普乐沙福用于外周血干细胞动员的研究进展  

Research advances in plerixafor peripheral blood stem cell mobilization

作　　者：邹德慧 邱录贵 Dehui Zou;Lugui Qiu(Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Tianjin 300020,China)

机构地区：[1]中国医学科学院血液病医院(中国医学科学院血液学研究所),实验血液学国家重点实验室,国家血液系统疾病临床医学研究中心,天津市300020

出　　处：《中国肿瘤临床》2021年第11期541-546,共6页Chinese Journal of Clinical Oncology

摘　　要：大剂量化疗联合自体外周血干细胞(peripheral blood stem cell,PBSC)移植是淋巴瘤和多发性骨髓瘤(multiple myeloma,MM)的有效治疗手段。PBSC的常规动员方案包括粒细胞集落刺激因子(granulocyte colony-stimulating factor,G-CSF)单用或联合化疗。部分患者使用常规动员方案无法采集到目标剂量的CD34+细胞,无法进行造血干细胞(hematopoietic stem cell,HSC)移植治疗。因此,针对动员不佳患者以及降低具有危险因素患者动员失败的风险,根据个体情况有效调整动员策略十分必要。普乐沙福是一种新型动员剂,联合G-CSF可显著提高CD34+细胞采集量,降低动员失败率的同时缩短采集天数,进而提高自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)效率,改善患者长期预后。本文对普乐沙福在PBSC动员的研究进展进行综述,旨在探讨普乐沙福适宜的动员人群、干预时机和路径,以优化PBSC的动员策略。High-dose chemotherapy followed by autologous peripheral blood stem cell(PBSC)transplantation is an effective treatment for both lymphoma and multiple myeloma(MM).Conventional PBSC mobilization protocols include treatment with granulocyte colony-stimulating factor(G-CSF)alone or in combination with chemotherapy.Stem cell transplantation cannot be successfully performed in many patients,because their CD34+cell counts are too low to meet the mobilization goal.Therefore,adjusting mobilization strategy in response to the conditions of individual patients is crucial,and requires pre-identification of poor mobilization to design strategies that minimize the risk of mobilization failure.Plerixafor is a novel stem cell mobilization agent.Combined with G-CSF,it has the capability to significantly increase the number of CD34+cells collected from peripheral blood,and reduce failure rates and the extent of apheresis needed,thereby improving both the efficacy of autologous hematopoietic stem cell transplantation(ASCT)and long-term prognosis.This article reviews research progress involving the use of plerixafor for PBSC mobilization,explores strategies for identifying the most responsive population,and investigates timing and treatment algorithms aimed at optimizing PBSC mobilization.

关 键 词：造血干细胞移植 外周血干细胞动员 普乐沙福 

分 类 号：R969[医药卫生—药理学]